Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling
Yueqin Bai, Yabin Gong, Ruifang Cui, Qingpeng Deng, Xiaozhen Zhao, Chang Liu, Longke Dong · 2025
Read Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling by Yueqin Bai, Yabin Gong, Ruifang Cui, Qingpeng Deng, Xiaozhen Zhao, Chang Liu, Longke Dong (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12776075.txt.
Introduction
Yueqin Bai and six co-authors test a toad-derived compound against resistant lung cancer in this two thousand twenty-five paper. The compound is bufalin, long used in traditional medicine. Lung cancers with a certain gene mutation often stop responding to targeted drugs. Bufalin had shown hints of beating that resistance. The team studied a resistant human lung cancer cell line in dishes and in mice.
They measured growth, cell death, and gene activity in a key growth pathway. That pathway runs from the mutated receptor through several relay proteins. Bufalin, alone and with a standard targeted drug, curbed the cancer cells. Tumors grown in mice gave a second check. The work is early, but it maps a possible partner drug for failing therapies.
Catalog record
| CREATOR | Yueqin Bai, Yabin Gong, Ruifang Cui, Qingpeng Deng, Xiaozhen Zhao, Chang Liu, Longke Dong |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling Authors: Yueqin Bai, Yabin Gong, Ruifang Cui, Qingpeng Deng, Xiaozhen Zhao, Chang Liu, Longke Dong Published: 2025 ABSTRACT BackgroundBufalin has shown potential in overcoming cancer resistance to osimertinib and sorafenib in epidermal growth factor receptor (EGFR)-mutated lung cancer. This study investigated the regulatory effect of bufalin on EGFR tyrosine kinase inhibitors (TKIs) resistance in lung cancer.MethodsThe cell experiments including the MTT assay, flow cytometry, and real-time polymerase chain reaction (RT-PCR) were used to determine the effects of bufalin and/or EGFR-TKIs gefitinib on the growth, proliferation, cycle, apoptosis, and expressions of genes linked to the EGFR-phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)-mammalian target of rapamycin (mTOR) signal pathway of human non-small cell lung cancer cell line H1975. In animal experiments, a model of H1975 cell subcutaneous graft tumor in severe combined immune deficiency (SCID) mice was created. Then bufalin and gefitinib were administered for three weeks by gavage and intraperitoneal injection, respectively. Tumor weight, volume, and other indicators were analyzed. In the meantime, RT-PCR and immunohistochemistry were performed to quantify key genes and proteins that were related to the EGFR-PI3K/Akt-mTOR signal pathway, including EGFR, PI3K, Akt, mTOR, 70 kDa ribosomal protein S6 kinase (p70S6K), and eukaryotic translation initiation factor 4E-binding protein (4E-BP) in tumor tissues of various intervention groups.ResultsBufalin and gefitinib could control the cell cycle, induce apoptosis, and impede H1975 cell development and growth. Furthermore, bufalin and gefitinib inhibited the growth of lung cancer tumor and decreased the expression of proteins pertinent to the EGFR-PI3K/Akt-mTOR pathway, including EGFR, Akt, mTOR, and p70S6K. These effects were more pronounced in the combined intervention group.ConclusionsBufalin can overcome gefitinib resistance in lung cancer by modulating the EGFR-PI3K/Akt-mTOR signaling pathway. Highlight box Key findings • Bufalin regulates epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resistance in lung cancer. In vitro/in vivo, it (alone/combined with gefitinib) impacts H1975 cell growth, apoptosis, and EGFR-PI3K/Akt-mTOR-related gene/protein expressions. Combined intervention shows stronger effects on cell cycle, apoptosis, tumor growth, and pathway-related proteins. What is known and what is new? • EGFR-TKIs mitigate lung cancer but face resistance. The EGFR-PI3K/Akt-mTOR pathway relates to tumor progression and TKI resistance. • Bufalin is a potential agent against EGFR-TKIs resistance. It modulates the pathway in H1975 cells (in vitro/xenografts) and enhances effects with gefitinib, offering a new resistance-overcoming approach. What is the implication, and what should change now? • Bufalin may act as an EGFR-TKIs (such as gefitinib) adjuvant for resistant lung cancer, improving efficacy via pathway targeting. • Conduct more pre-clinical research on mechanisms/dosing. Perform clinical trials to test bufalin’s safety/efficacy in resistant patients, accelerating translation. Introduction Due to a fatality rate of almost 21%, lung cancer is presently one of the leading culprits of cancer-related deaths worldwide (1). Non-small cell lung cancer (NSCLC) accounts for 80% to 90% of lung cancer patients (2), and about 60% of NSCLC patients are diagnosed at advanced or metastatic stages (2). Epidermal growth factor receptor (EGFR), a member of the tyrosine kinases family, is a key transmembrane glycoprotein that regulates the proliferation, survival, differentiation and metastasis of cancer cells (3,4). Previous research has revealed that NSCLC development is accompanied by activated EGFR mutations and overexpression of EGFR protein in malignant tumors, based on which targeted treatment regimens for EGFR continue to evolve (5). First-generation EGFR-tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have been initially established as first-line options for patients with classic activating mutations (e.g., exon 19 deletions or L858R) (6). However, acquired resistance invariably develops, and its mechanisms are complicated, mainly including target gene modification replacement pathway activation and histological or phenotypic transformation, with the EGFR T790M mutation as the most prevalent mechanism (3,7,8). The second-generation TKIs have therefore been designed and developed to address T790M resistance, such as dacomitinib and afatinib. However, their clinical utility is limited by low selectivity for mutant EGFR and potential toxicity (9). Osimertinib, a third-generation, central nervous system (CNS)-active TKI designed to target the T790M mutation, has now become the preferred first-line standard of care due to its superior efficacy and improved tolerability profile compared to earlier agents (6). The evolution of these therapies and their associated resistance mechanisms remains a focus of ongoing research. Some studies have found that EGFR-TKIs combined with cytotoxic drugs can synergically ameliorate EGFR-mutated lung cancer, such as erlotinib combined with cisplatin that can prevent lung cancer cells from proliferating, and pemetrexed treatment that can reduce the acquired resistance of EGFR-mutated lung cancer cells to gefitinib (10,11). These new treatment strategies offer promising alternatives for lung cancer patients who are resistant to EGFR-TKIs. Bufalin is a natural digoxin component derived from traditional Chinese medicine, Chan Su, which has significant anti-tumor effects and has been confirmed as an effective inhibitor of NSCLC cell proliferation among various extracts of toads (12,13). Its broad anti-cancer effects have been widely unveiled across multiple cancer types, including lung (14,15), liver (16), breast (17), head and neck (18), as well as melanoma (19) cancers. The anti-cancer mechanisms of bufalin mainly consist of promoting apoptosis of cancer cells, inducing cell cycle arrest, and inhibiting cell differentiation, migration and inflammation (20). For instance, bufalin can promote the apoptosis of oral and bladder cancer cells through mitochondria-dependent pathway, and can also impede the growth of stomach or colorectal cancer cells by interfering with the cell cycle (18). In the treatment of lung cancer, bufalin can hinder the growth of NSCLC cells and cause cell death by regulating circ_0046264/miR-522-3p pathway, inhibiting the expression of CDK9, and down-regulating Axl protein and other mechanisms (12,21,22). It is worth noting that bufalin has also shown potential in overcoming cancer resistance to osimertinib and sorafenib in EGFR-mutated lung cancer (23,24). While previous research has demonstrated that bufalin can reverse HGF-induced EGFR-TKI resistance by inhibiting the Met/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway (25), its efficacy against the intrinsic resistance driven by the EGFR T790M mutation remains unclear. Furthermore, its impact on the downstream mammalian target of rapamycin (mTOR) signaling axis, a critical component of the PI3K network, has not been explored. Therefore, this study aims to investigate the effect and underlying mechanism of bufalin alone and in combination with gefitinib, on overcoming L858R/T790M-mediated resistance in vitro and in vivo, with a specific focus on the complete EGFR-PI3K/Akt-mTOR signaling pathway. In this work, we used both in vitro and in vivo tests to examine the impact of bufalin on NSCLC patients’ acquired resistance to gefitinib, and explored the relevant mechanism of action. Our study found that bufalin can improve EGFR-TKIs gefitinib resistance in H1975 cells (harboring the classic EGFR L858R/T790M mutation complex) and severe combined immune deficiency (SCID) mice with H1975 xenografts by modulating the EGFR-PI3K/Akt-mTOR signaling pathway. These findings offer a fresh approach to treating lung cancer patients’ resistance to EGFR-TKIs. We present this article in accordance with the MDAR and ARRIVE reporting checklists (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-1217/rc). Methods Materials and reagents The cell bank of the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (SCSP-597, Shanghai, China), provided the NCI-H1975 cell line (human lung adenocarcinoma cells), which was identified by STR. Bufalin was obtained from the MedChemExpress (HY-N0877, Monmouth Junction, NJ, USA). Gefitinib was provided by Selleck (S1025, Houston, TX,